Evidence map›Paper›PMID 40128740›Full record

ArticleMolecular cancer2025

Circular RNA circDCUN1D4 suppresses hepatocellular carcinoma development via targeting the miR-590-5p/ TIMP3 axis.

Hongyu Li, Bing Su, Yan Jiang, Boyang Zhang, Rulong Du, Can Song, Bin Hou, Kun Xu, Lida Wu, Yuchun Gu

RetractedAbstract readRetracted Publication
In one paragraph

Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Recent advances of circular RNAs in gastrointestinal cancer.World journal of clinical oncology · 2025
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Hongyu LiCollege of Chemistry and Lie Science, Beijing University of Technology, Beijing, 100124, China. leinade123@126.com.
Bing SuCollege of Chemistry and Lie Science, Beijing University of Technology, Beijing, 100124, China.
Yan JiangDepartment of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Boyang ZhangAllife Medical Science and Technology Co., Ltd. Economic and Technological Development Zone, Beijing, 100176, China.
Rulong DuAllife Medical Science and Technology Co., Ltd. Economic and Technological Development Zone, Beijing, 100176, China.
Can SongAllife Medical Science and Technology Co., Ltd. Economic and Technological Development Zone, Beijing, 100176, China.
Bin HouAllife Medical Science and Technology Co., Ltd. Economic and Technological Development Zone, Beijing, 100176, China.
Kun XuCollege of Chemistry and Lie Science, Beijing University of Technology, Beijing, 100124, China. kunxu@bjut.edu.cn.
Lida WuAllife Medical Science and Technology Co., Ltd. Economic and Technological Development Zone, Beijing, 100176, China. wldpaper@pku.edu.cn.
Yuchun GuAllife Medical Science and Technology Co., Ltd. Economic and Technological Development Zone, Beijing, 100176, China. ycgu@pku.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a major global health concern, necessitating innovative therapeutic strategies. In this study, we investigated the functional role of circular RNA circDCUN1D4 in HCC progression and its potential therapeutic implications. It was found that HCC patients exhibiting higher levels of circDCUN1D4 demonstrated a more favorable survival rate. Furthermore, we revealed that circDCUN1D4 suppressed HCC cell proliferation, migration, and invasion. Mechanistically, circDCUN1D4 was identified as a sponge for miR-590-5p, leading to the downregulation of its downstream target, Tissue Inhibitor of Metalloproteinase 3 (TIMP3). Importantly, circDCUN1D4 administration through In vivo jet-PEI exhibited a robust inhibitory effect on tumor progression without causing notable toxicity in mice. Overall, our findings highlight circDCUN1D4 as a promising therapeutic candidate for HCC, unraveling its intricate regulatory role through the miR-590-5p/TIMP3 axis. This study contributes valuable insights into the potential clinical applications of circRNA-based therapies for HCC.

Indexed as

Carcinoma, HepatocellularGene Expression Regulation, NeoplasticLiver NeoplasmsMicroRNAsRNA, CircularTissue Inhibitor of Metalloproteinase-3AnimalsCell Line, TumorCell MovementCell ProliferationHumansMaleMiceXenograft Model Antitumor AssaysMicroRNAsMIRN590 microRNA, humanRNA, CircularTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3circDCUN1D4Hepatocellular carcinomamiR-590-5pTIMP3

Identifiers

PMID40128740
PMCPMC11934760

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.